Oxygenta Pharmaceutical announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 May 2024 .Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 8 April 2024.Powered by Capital Market - Live News

Net Loss of Oxygenta Pharmaceutical reported to Rs 3.36 crore in the quarter ended December 2023 as against net loss of Rs 3.25 crore during the previous quarter ended December 2022. Sales rose 16.56% to Rs 9.15 crore in the quarter ended December 2023 as against Rs 7.85 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales9.157.85 17 OPM %-27.10-29.68 - PBDT-2.81-2.51 -12 PBT-3.50-2.91 -20 NP-3.36-3.25 -3 Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 February 2024.Powered by Capital Market - Live News

Net Loss of Oxygenta Pharmaceutical reported to Rs 3.16 crore in the quarter ended September 2023 as against net loss of Rs 2.34 crore during the previous quarter ended September 2022. Sales rose 115.84% to Rs 13.08 crore in the quarter ended September 2023 as against Rs 6.06 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales13.086.06 116 OPM %-15.14-24.75 - PBDT-2.32-1.60 -45 PBT-3.15-2.00 -58 NP-3.16-2.34 -35 Powered by Capital Market - Live News